http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
-
Nuvalent Inc (NUVL) Initiates Phase 2 Portion of ARROS-1 Clinical Trial
-
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
-
Nuvalent to Participate in Upcoming September Investor Conferences
-
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
-
Nuvalent to Participate in Upcoming August Investor Conferences
-
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
-
Nuvalent Inc (NUVL) Plans to Report Preliminary Phase 1 Dose-Escalation Data for NVL-655 in H2'23; Reports Q1
-
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
-
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days
-
Nuvalent Inc (NUVL) Presents New Preclinical Data Supporting NVL-655
-
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023
-
Nuvalent Inc (NUVL) to Present ALKOVE-1 Trial in Progress
-
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
-
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
-
Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference
-
Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Nuvalent Inc (NUVL) Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
-
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
-
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
-
Nuvalent (NUVL) Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial
-
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC
-
Nuvalent Inc (NUVL) Reports New Preclinical Data for NVL-330 and NVL-655
-
Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655
-
Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium
-
Nuvalent Inc (NUVL) Appoints Michael L. Meyers to its Board
-
Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors
-
Nuvalent Inc (NUVL) to Present Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at ENA
-
Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates
-
Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference
-
Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results
-
Nuvalent Inc (NUVL) Reports Preclinical Data Supporting Potential Best-in-Class Profile for Inhibitor NVL-655
-
Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
-
Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference
-
Nuvalent Inc (NUVL) Promotes Darlene Noci to Chief Development Officer
-
Nuvalent Announces Leadership Promotions
-
Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
-
Nuvalent Inc (NUVL) Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers
-
Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers
-
Nuvalent to Present at the 2022 Jefferies Healthcare Conference
-
Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results
-
Nuvalent Inc (NUVL) Presents Expanded Data Showing Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR
-
Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
-
Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference
-
Nuvalent (NUVL) Appoints Anna Protopapas as Chair of Board of Directors
-
Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
-
Nuvalent Inc (NUVL) Reports Pipeline and Business Progress, Announces Q4 Results
-
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
-
Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
